Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
34.43
-0.46 (-1.32%)
Aug 20, 2026, 3:33 PM EDT - Market open
Alto Neuroscience Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 243.73 | 176.48 | 168.23 | 82.55 | 48.34 | 25.71 |
Cash & Short-Term Investments | 243.73 | 176.48 | 168.23 | 82.55 | 48.34 | 25.71 |
Cash Growth | 65.15% | 4.91% | 103.79% | 70.75% | 88.07% | - |
Accounts Receivable | - | - | - | - | - | 1.5 |
Other Receivables | - | - | - | - | 0.33 | 0.25 |
Receivables | - | - | - | - | 0.33 | 1.74 |
Prepaid Expenses | 3.59 | 1.23 | 1.11 | 0.52 | 0.33 | 0.24 |
Other Current Assets | - | - | - | 2.32 | 0.21 | - |
Total Current Assets | 247.32 | 177.72 | 169.34 | 85.39 | 49.22 | 27.68 |
Property, Plant & Equipment | 5.91 | 6.13 | 7.7 | 1.23 | 1.58 | 1.06 |
Other Long-Term Assets | 0.84 | 0.84 | 0.5 | 0.01 | 0.06 | 0.05 |
Total Assets | 254.07 | 184.69 | 177.54 | 86.63 | 50.85 | 28.79 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4.02 | 1.88 | 1.58 | 1.07 | 1.61 | 0.6 |
Accrued Expenses | 7.5 | 7.71 | 7.56 | 3.5 | 3.67 | 0.93 |
Current Portion of Long-Term Debt | 3.77 | 0.59 | - | - | - | - |
Current Portion of Leases | 1.36 | 1.15 | 0.87 | 0.13 | 0.28 | - |
Other Current Liabilities | - | - | - | 0.92 | - | 0.28 |
Total Current Liabilities | 16.65 | 11.33 | 10.01 | 5.61 | 5.56 | 1.81 |
Long-Term Debt | 14.88 | 18.4 | 11.56 | 9.86 | 9.47 | - |
Long-Term Leases | 3.28 | 3.82 | 4.52 | - | 0.12 | - |
Total Liabilities | 34.82 | 33.55 | 26.08 | 15.47 | 15.15 | 1.81 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | - | - | 0 |
Additional Paid-In Capital | 474.74 | 352.75 | 289.95 | 5.37 | 2.3 | 0.49 |
Retained Earnings | -255.51 | -201.63 | -138.4 | -76.97 | -40.66 | -12.95 |
Comprehensive Income & Other | 0.02 | 0.02 | -0.1 | -0.08 | -0.05 | -0.02 |
Total Common Equity | 219.25 | 151.14 | 151.46 | -71.67 | -38.41 | -12.48 |
Shareholders' Equity | 219.25 | 151.14 | 151.46 | 71.16 | 35.71 | 26.98 |
Total Liabilities & Equity | 254.07 | 184.69 | 177.54 | 86.63 | 50.85 | 28.79 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 23.29 | 23.96 | 16.94 | 9.99 | 9.87 | - |
Net Cash (Debt) | 220.44 | 152.53 | 151.29 | 72.56 | 38.47 | 25.71 |
Net Cash Growth | 83.28% | 0.82% | 108.49% | 88.61% | 49.67% | - |
Net Cash Per Share | 6.23 | 5.29 | 6.15 | 19.45 | 11.16 | 10.65 |
Filing Date Shares Outstanding | 39.24 | 31.95 | 27.07 | 26.86 | 3.69 | 2.41 |
Total Common Shares Outstanding | 35.09 | 31.92 | 26.99 | 3.81 | 3.69 | 2.41 |
Working Capital | 230.67 | 166.39 | 159.33 | 79.78 | 43.66 | 25.87 |
Book Value Per Share | 6.25 | 4.73 | 5.61 | -18.81 | -10.40 | -5.17 |
Tangible Book Value | 219.25 | 151.14 | 151.46 | -71.67 | -38.41 | -12.48 |
Tangible Book Value Per Share | 6.25 | 4.73 | 5.61 | -18.81 | -10.40 | -5.17 |
Machinery | 3.12 | 2.58 | 2.75 | 1.27 | 1.2 | 0.88 |
Leasehold Improvements | 0.25 | 0.25 | 0.25 | - | - | - |